Vivos Therapeutics, Inc. (VVOS) has 12 open-market insider trades by 3 insiders since 2020. The most active filer is Ronald Kirk Huntsman, CEO.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Michael C. Skaff | 10% Owner | — | 1 | $1.8M | 2026-06-30 |
| Ronald Kirk Huntsman | CEO | — | 9 | $116K | 2023-06-20 |
| Bradford K. Amman | CAO | — | 2 | $13K | 2026-07-31 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Michael C. Skaff | 10% Owner | Buy | $1.8M | 2026-03-31 |
| Ronald Kirk Huntsman | CEO | Buy | $7K | 2023-06-20 |
| Ronald Kirk Huntsman | CEO | Buy | $8K | 2023-06-15 |
| Ronald Kirk Huntsman | CEO | Buy | $5K | 2023-06-14 |
| Ronald Kirk Huntsman | CEO & 10% | Buy | $10K | 2022-12-23 |
| Ronald Kirk Huntsman | CEO & 10% | Buy | $24K | 2022-05-31 |
Companies that share insiders with VVOS, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| Ronald Kirk Huntsman | CEO | Buy | $22K | 2021-09-21 |
| Ronald Kirk Huntsman | CEO | Buy | $15K | 2021-08-17 |
| Bradford K. Amman | CFO | Buy | $5K | 2021-05-25 |
| Ronald Kirk Huntsman | CEO | Buy | $22K | 2021-05-25 |
| Bradford K. Amman | CFO | Buy | $7K | 2020-12-24 |
| Ronald Kirk Huntsman | CEO & 10% | Buy | $4K | 2020-12-11 |